- Home
- TNGX vs PFN Comparison
TNGX vs PFN Comparison
Compare TNGX & PFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- PFN
- Stock Information
- Founded
- TNGX 2014
- PFN 2004
- Country
- TNGX United States
- PFN United States
- Employees
- TNGX N/A
- PFN N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- PFN Finance/Investors Services
- Sector
- TNGX Health Care
- PFN Finance
- Exchange
- TNGX Nasdaq
- PFN Nasdaq
- Market Cap
- TNGX 723.2M
- PFN 692.7M
- IPO Year
- TNGX N/A
- PFN N/A
- Fundamental
- Price
- TNGX $6.63
- PFN $7.60
- Analyst Decision
- TNGX Strong Buy
- PFN
- Analyst Count
- TNGX 6
- PFN 0
- Target Price
- TNGX $10.00
- PFN N/A
- AVG Volume (30 Days)
- TNGX 1.3M
- PFN 331.7K
- Earning Date
- TNGX 11-05-2025
- PFN 01-01-0001
- Dividend Yield
- TNGX N/A
- PFN 11.66%
- EPS Growth
- TNGX N/A
- PFN N/A
- EPS
- TNGX N/A
- PFN N/A
- Revenue
- TNGX $24,296,000.00
- PFN N/A
- Revenue This Year
- TNGX $6.56
- PFN N/A
- Revenue Next Year
- TNGX N/A
- PFN N/A
- P/E Ratio
- TNGX N/A
- PFN N/A
- Revenue Growth
- TNGX N/A
- PFN N/A
- 52 Week Low
- TNGX $1.03
- PFN $5.94
- 52 Week High
- TNGX $10.85
- PFN $7.58
- Technical
- Relative Strength Index (RSI)
- TNGX 49.24
- PFN 52.93
- Support Level
- TNGX $6.25
- PFN $7.49
- Resistance Level
- TNGX $7.40
- PFN $7.67
- Average True Range (ATR)
- TNGX 0.40
- PFN 0.04
- MACD
- TNGX -0.05
- PFN 0.00
- Stochastic Oscillator
- TNGX 33.04
- PFN 46.43
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About PFN PIMCO Income Strategy Fund II
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.